Dissemination of VIM-2 producing Pseudomonas aeruginosa ST233 at tertiary care hospitals in Egypt

Zafer, Mai Mahmoud; Al-Agamy, Mohamed Hamed; El-Mahallawy, Hadir Ahmed; Amin, Magdy Aly; El Din Ashour, Seif

doi:10.1186/s12879-015-0861-8

BMC Infectious Diseases

Table 2 Isolation details, VIM-2 gene results, MICs and sequence type of 33 P.aeruginosa MBL positive isolates

From: Dissemination of VIM-2 producing Pseudomonas aeruginosa ST233 at tertiary care hospitals in Egypt

Isolate	Duration of episode in days	Sample	Hospital	VIM-2	NDM-1	IMP-1	PM	PTc	TZ	TZL	CI	AK	GM	IP	CT	Sequence type (ST)
1	21	Wound	KAA	+	-	-	≥256	16	≥256	≥256	2	12	3	≥32	≥256
2	9	Blood	KAA	+	-	-	12	64	8	3	≥32	16	≥256	≥32	≥256
3	36	Wound	KAA	+	+	-	8	64	64	24	≥32	≥256	12	≥32	≥256	233
4	30	Wound	KAA	+	-	-	4	3	6	2	≥32	≥256	≥256	≥32	32	233
5	13	Wound	KAA	+	-	-	4	3	6	1.5	≥32	≥256	≥256	≥32	32
6	8	Wound	KAA	+	+	-	64	≥256	≥256	≥256	≥32	≥256	≥256	≥32	≥256	233
7	5	Wound	KAA	+	-	-	24	≥256	≥256	192	≥32	≥256	12	≥32	≥256
8	10	Wound	KAA	+	-	-	6	96	96	24	0.094	4	2	≥32	≥256
9	10	Urine	KAA	+	-	-	≥256	3	≥256	≥256	≥32	32	12	≥32	≥256	303
10	9	Blood	KAA	+	-	-	2	4	1.5	≥32	2	2	≥32	16	≥256
11	75	Sputum	KAA	+	-	-	≥256	≥256	≥256	≥256	≥32	≥256	32	≥32	≥256
12	4	Wound	KAA	+	-	-	6	24	8	16	≥32	≥256	1.5	≥32	≥256	198
13	30	Urine	NCI	+	-	-	≥256	≥256	≥256	≥256	≥32	≥256	≥256	≥32	≥256	629
14	10	Sputum	NCI	-	-	-	≥256	24	≥256	≥256	1	6	2	≥32	≥256
15	30	Wound	NCI	-	-	+	16	24	16	4	≥32	12	≥256	≥32	≥256
16	46	Wound	NCI	+	-	-	≥256	≥256	48	8	≥32	96	≥256	≥32	≥256	233
17	22	Sputum	NCI	+	-	-	6	12	12	2	≥32	6	≥256	≥32	≥256	507
18	70	Sputum	NCI	-	-	-	≥256	4	≥256	≥256	≥32	96	32	≥32	≥256
19	65	Sputum	NCI	+	-	-	≥256	≥256	≥256	96	0.094	96	32	≥32	≥256	406
20	120	Sputum	NCI	+	-	-	64	32	12	2	≥32	16	≥256	≥32	≥256	303
21	54	Wound	KAA	+	-	-	8	16	24	4	≥32	48	≥256	≥32	≥256	233
22	27	Wound	KAA	+	-	-	16	≥256	≥256	≥256	≥32	128	32	≥32	≥256	274
23	7	wound	KAA	+	-	-	256	≥256	≥56	256	≥32	≥256	32	≥32	≥256	884
24	45	Urine	KAA	+	-	-	8	12	≥256	4	0.064	8	≥256	≥32	≥256	738
25	150	urine	KAA	+	-	-	≥256	≥256	≥256	128	≥32	48	32	≥32	≥256	274
26	75	Wound	KAA	+	-	-	≥256	≥256	≥256	≥256	≥32	≥256	≥256	≥32	≥256	683
27	21	Urine	KAA	+	-	-	16	≥256	≥256	32	0.064	8	32	≥32	≥256	990
28	45	Urine	KAA	-	-	-	64	≥256	≥256	≥256	0.064	32	32	≥32	≥256
29	240	Urine	KAA	+	-	-	2	4	12	2	0.125	4	2	≥32	≥256	233
30	180	Urine	KAA	+	-	-	2	4	8	1.5	0.125	4	2	≥32	≥256	233
31	21	Wound	KAA	+	-	-	8	128	6	24	0.094	6	2	≥32	≥256
32	30	Wound	KAA	-	-	-	12	32	2	8	0.064	6	2	≥32	≥256
33	21	Ear swab	KAA	+	-	-	6	6	≥256	8	3	≥32	128	16	≥32	233

PM = cefepime, PTc = piperacillin/tazobactam, TZL = ceftazidime/clavulanic acid, TZ = ceftazidime, CI = ciprofloxacin, AK = amikacin, GM = gentamicin, IP = imipenem, CT = cefotaxime.

Back to article page

ISSN: 1471-2334

Contact us

General enquiries: journalsubmissions@springernature.com